NCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
Clinical Trials
9 trialsNCT07441512 2026-03-02
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07333937 2026-01-12
NETHER
Xijing Hospital
Phase 2 Not yet recruiting
NCT07255612 2025-12-01
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting
NCT06731153 2024-12-12
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
Fudan University
Phase 2 Not yet recruiting
NCT06539559 2024-08-06
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06308939 2024-03-13
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06202313 2024-01-11
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
Shengjing Hospital
Phase 2 Not yet recruiting